Slow but Steady: t(11;14) Myeloma Shows Superior Outcomes Despite Delayed MRD Negativity with Quadruplet Therapy

Background

The t(11;14) translocation defines a unique biological subset of multiple myeloma (MM) characterized by cyclin D1 overexpression and historically intermediate prognosis. With the advent of quadruplet induction regimens (QUAD) incorporating CD38 monoclonal antibodies, proteasome inhibitors, immunomodulatory drugs, and corticosteroids followed by autologous stem cell transplantation (ASCT), depth of response measured by measurable residual disease (MRD) has emerged as a critical prognostic marker. This study examines the paradoxical relationship between delayed MRD clearance and superior progression-free survival (PFS) in t(11;14)+ MM patients treated with contemporary protocols.

Study Design

The retrospective cohort analysis evaluated 302 newly diagnosed MM patients (NDMM) receiving QUAD induction (daratumumab-bortezomib-lenalidomide-dexamethasone or isatuximab-based regimens) with ASCT and MRD-adapted maintenance. Centralized next-generation flow cytometry (EuroFlow, sensitivity 10-5) assessed MRD at serial timepoints: post-induction, post-ASCT, and during maintenance. The primary cohort comparison was between 47 t(11;14)+ and 255 t(11;14)- patients, with median follow-up of 45.8 months.

Key Findings

MRD Dynamics

t(11;14)+ patients demonstrated significantly slower MRD clearance: MRD <10-5 rates were 9% vs 31% post-induction (p=0.002), 36% vs 59% post-ASCT (p=0.008), and 53% vs 75% at any timepoint (p=0.003). Median time to achieve MRD <10-5 was nearly doubled (13.6 vs 7.7 months, p<0.001). The sustained MRD negativity (<10-5 for ≥12 months) rates were comparable (38% vs 46%, p=0.36).

Survival Outcomes

Despite slower MRD conversion, t(11;14)+ patients had superior 4-year PFS (90% vs 72%, HR 0.38, 95% CI 0.18-0.79) and trended toward better OS (94% vs 85%, p=0.12). Multivariable analysis confirmed sustained MRD negativity as the strongest prognostic factor (HR 0.21, 95% CI 0.08-0.52), with no progressions observed in t(11;14)+ patients achieving S-MRD <10-5 (0/18 vs 11/29 in S-MRD positive, p<0.001).

Biological Correlates

The authors postulate that the indolent MRD kinetics may reflect lower tumor proliferative rates in t(11;14)+ disease, while the exquisite sensitivity to BCL-2 inhibition (not used in this cohort) suggests preserved apoptotic machinery contributing to durable responses once MRD negativity is achieved.

Expert Commentary

Dr. Shaji Kumar (Mayo Clinic, uninvolved in the study) noted: ‘These findings challenge our dogma that faster MRD clearance always predicts better outcomes. The t(11;14) population may benefit from extended therapy duration rather than early regimen intensification.’ The study’s limitation includes its retrospective design and heterogeneous maintenance approaches (67% received anti-CD38 continuation).

Conclusion

t(11;14)+ MM demonstrates delayed but highly consequential MRD responses to QUAD/ASCT therapy, warranting distinct response assessment timelines. These patients achieve excellent long-term control despite slower MRD clearance, supporting MRD-adapted duration rather than abandonment of effective regimens. Prospective validation of BCL-2 inhibitor combinations in this subset is warranted.

Funding

Research reported in this publication was supported by the National Cancer Institute of the National Institutes of Health under Award Number P30CA016086. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.

References

1. Bal S, et al. Blood. 2026;147(16):1857-1862. PMID: 41592281

2. Kumar S, et al. Blood Cancer J. 2024;14:12. PMID: 41176523